Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:ARVNNASDAQ:KRTXNASDAQ:MORNASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$28.75-0.9%$30.12$22.90▼$36.45$4.76B0.441.73 million shs1.12 million shsARVNArvinas$7.89-0.1%$7.30$5.90▼$34.11$580.28M2.171.46 million shs826,658 shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APCRXPacira BioSciences$23.210.0%$25.17$11.16▼$27.64$1.07B0.48915,165 shs202,316 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-0.21%-8.85%-4.36%+18.65%ARVNArvinas0.00%+4.66%+13.54%+20.29%-66.98%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%MORMorphoSys0.00%0.00%0.00%0.00%+4.18%PCRXPacira BioSciences0.00%-1.17%-13.99%+0.45%+7.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.9369 of 5 stars4.43.00.04.23.42.51.9ARVNArvinas3.1189 of 5 stars4.32.00.00.00.02.51.3KRTXKaruna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/APCRXPacira BioSciences3.4624 of 5 stars2.22.00.03.92.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.83Moderate Buy$40.0039.13% UpsideARVNArvinas 2.55Moderate Buy$20.29157.12% UpsideKRTXKaruna Therapeutics 0.00N/AN/AN/AMORMorphoSys 0.00N/AN/AN/APCRXPacira BioSciences 2.33Hold$26.4413.96% UpsideCurrent Analyst Ratings BreakdownLatest KRTX, ARVN, ALKS, PCRX, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/9/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $30.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.04$2.64 per share10.88$9.05 per share3.18ARVNArvinas$263.40M2.19N/AN/A$8.17 per share0.97KRTXKaruna Therapeutics$654K19,239.07N/AN/A$33.24 per share9.92MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17PCRXPacira BioSciences$700.97M1.53$4.31 per share5.38$16.86 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0913.7620.991.7923.30%27.52%17.98%7/23/2025 (Estimated)ARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)KRTXKaruna Therapeutics-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/APCRXPacira BioSciences-$99.56M-$2.28N/A9.03N/A-14.78%13.78%7.00%7/29/2025 (Estimated)Latest KRTX, ARVN, ALKS, PCRX, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025ARVNArvinas-$0.87N/AN/AN/A$34.42 millionN/A7/29/2025Q2 2025PCRXPacira BioSciences$0.73N/AN/AN/A$183.11 millionN/A7/23/2025Q2 2025ALKSAlkermes$0.42N/AN/AN/A$343.20 millionN/A5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AKRTXKaruna TherapeuticsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.332.92ARVNArvinasN/A4.584.58KRTXKaruna TherapeuticsN/A19.3119.31MORMorphoSys4.981.381.38PCRXPacira BioSciences0.482.411.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%ARVNArvinas95.19%KRTXKaruna TherapeuticsN/AMORMorphoSys18.38%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%ARVNArvinas4.73%KRTXKaruna Therapeutics13.20%MORMorphoSys0.05%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableARVNArvinas42072.99 million69.54 millionOptionableKRTXKaruna Therapeutics33938.15 million33.16 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionablePCRXPacira BioSciences72046.29 million43.33 millionOptionableKRTX, ARVN, ALKS, PCRX, and MOR HeadlinesRecent News About These CompaniesPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3 at 4:01 PM | globenewswire.comRobeco Institutional Asset Management B.V. Purchases 12,750 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)July 2 at 4:01 AM | marketbeat.comPacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025June 18, 2025 | finance.yahoo.comIs the Options Market Predicting a Spike in Pacira BioSciences Stock?June 18, 2025 | zacks.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from AnalystsJune 18, 2025 | marketbeat.comPACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 17, 2025 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Assenagon Asset Management S.A.June 14, 2025 | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 14, 2025 | marketbeat.comPacira Pharmaceuticals Stockholders Approve Amended Incentive PlanJune 13, 2025 | tipranks.comBridge City Capital LLC Reduces Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 9, 2025 | marketbeat.comPacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationJune 8, 2025 | accessnewswire.comAUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 21,781 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)June 8, 2025 | marketbeat.comLauren Riker Sells 5,578 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockJune 7, 2025 | insidertrades.comPacira BioSciences (NASDAQ:PCRX) Upgraded at Wall Street ZenJune 6, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) SVP Sells $146,199.38 in StockJune 6, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comPacira BioSciences’s First Quarter 2025 Misses EstimatesMay 29, 2025 | ryortho.comRBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach OutMay 25, 2025 | accessnewswire.comAPacira at RBC Conference: Strategic Growth and Gene Therapy FocusMay 23, 2025 | uk.investing.comPacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%May 22, 2025 | finance.yahoo.comPacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesMay 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseChina Market Movers: MCHI, PDD, BIDU Show Bullish TrendsBy Gabriel Osorio-Mazilli | June 16, 2025View China Market Movers: MCHI, PDD, BIDU Show Bullish TrendsTariff Talks Advance, What Taiwan Semiconductor Can DeliverBy Gabriel Osorio-Mazilli | June 16, 2025View Tariff Talks Advance, What Taiwan Semiconductor Can DeliverKRTX, ARVN, ALKS, PCRX, and MOR Company DescriptionsAlkermes NASDAQ:ALKS$28.75 -0.25 (-0.86%) Closing price 07/3/2025 03:26 PM EasternExtended Trading$28.75 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Arvinas NASDAQ:ARVN$7.89 -0.01 (-0.11%) Closing price 07/3/2025 02:37 PM EasternExtended Trading$7.96 +0.07 (+0.87%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Karuna Therapeutics NASDAQ:KRTXKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/3/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Pacira BioSciences NASDAQ:PCRX$23.20 -0.01 (-0.02%) As of 07/3/2025 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
